ImmunityBio, Inc.
IBRX
$7.25
$0.081.12%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.40% | 20.43% | |||
| Total Other Revenue | 200.00% | -95.37% | |||
| Total Revenue | 15.47% | 19.41% | |||
| Cost of Revenue | -37.70% | 115.82% | |||
| Gross Profit | 16.00% | 18.88% | |||
| SG&A Expenses | 29.55% | -5.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.71% | 17.42% | |||
| Operating Income | -7.90% | -16.27% | |||
| Income Before Tax | -919.10% | 7.75% | |||
| Income Tax Expenses | 106.67% | -285.71% | |||
| Earnings from Continuing Operations | -921.33% | 7.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 7.14% | -33.33% | |||
| Net Income | -921.54% | 7.89% | |||
| EBIT | -7.90% | -16.27% | |||
| EBITDA | -7.38% | -17.88% | |||
| EPS Basic | -884.35% | 11.83% | |||
| Normalized Basic EPS | -870.92% | 11.71% | |||
| EPS Diluted | -871.92% | 10.70% | |||
| Normalized Diluted EPS | -870.92% | 11.71% | |||
| Average Basic Shares Outstanding | 3.76% | 4.55% | |||
| Average Diluted Shares Outstanding | 3.76% | 4.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||